Schrodinger, Inc. (SDGR)
Data as of , from SEC Form 4 filings.
See up to 3 months of SDGR. The 7-day demo opens the 1M and 3M ranges and puts SDGR on your watchlist.
Start 7-day demoLatest SDGR insider trades
About Schrodinger, Inc. (SDGR)
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
- NEW YORK, NY
- 850
- 2020
- XNAS
SDGR Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 32,474 | $942K |
| Option exercise | 2 | 63,198 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
SDGR insider transactions (Form 4)
6938 Form 4 filings on record, the earliest from Oct 16, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Karen Akinsanya - Officer | Option exercise | Common Stock | 31,599 | $4.34 | $137K | |
| Karen Akinsanya - Officer | Open-market sale | Common Stock | 10,000 | $28.00 | $280K | |
| Karen Akinsanya - Officer | Open-market sale | Common Stock | 21,599 | $30.00 | $648K | |
| Karen Akinsanya - Officer | Option exercise | Stock Option (right to buy) | 31,599 | $0.00 | - | |
 Rachit Jain - Officer | Open-market sale | Common Stock | 875 | $15.60 footnote F2 | $14K | |
| ||||||
 Richard Friesner - Director | Gift | Common Stock | 679,373 | $0.00 | - | |
| Richard Friesner - Director | Gift | Common Stock | 679,373 | $0.00 | - | |
| Arun Oberoi - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Arun Oberoi - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
 Jeffrey Chodakewitz - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
| Jeffrey Chodakewitz - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Richard Friesner - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
| Richard Friesner - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Gary L. Ginsberg - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Gary L. Ginsberg - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
| Rosana Kapeller-Libermann - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Rosana Kapeller-Libermann - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
 Michael Lynton - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
| Michael Lynton - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Gary Sender - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
| Gary Sender - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Nancy Thornberry - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Nancy Thornberry - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
 Kralingen Bridget A. van - Director | Grant or award | Common Stock | 8,141 | $0.00 | - | |
| Kralingen Bridget A. van - Director | Grant or award | Stock Option (right to buy) | 13,313 | $0.00 | - | |
 Ramy Farid - Officer | Option exercise | Common Stock | 43,000 | $3.07 | $132K | |
| Ramy Farid - Officer | Open-market sale | Common Stock | 43,000 | $12.33 footnote F2 | $530K | |
| Ramy Farid - Officer | Option exercise | Common Stock | 43,000 | $3.07 | $132K | |
| Ramy Farid - Officer | Open-market sale | Common Stock | 43,000 | $12.21 footnote F3 | $525K | |
| Ramy Farid - Officer | Option exercise | Common Stock | 74,527 | $3.07 | $229K | |
| Ramy Farid - Officer | Option exercise | Stock Option (right to buy) | 43,000 | $0.00 | - | |
| Ramy Farid - Officer | Option exercise | Stock Option (right to buy) | 43,000 | $0.00 | - | |
| Ramy Farid - Officer | Option exercise | Stock Option (right to buy) | 74,527 | $0.00 | - | |
| ||||||
| Rachit Jain - Officer | Open-market sale | Common Stock | 844 | $12.75 footnote F2 | $11K | |
| ||||||
| Jenny Herman - Officer | Open-market sale | Common Stock | 775 | $12.85 footnote F2 | $10K | |
| Jenny Herman - Officer | Open-market sale | Common Stock | 608 | $12.84 footnote F3 | $8K | |
| ||||||
| Rachit Jain - Officer | Open-market sale | Common Stock | 1,631 | $12.90 footnote F2 | $21K | |
| ||||||
| Yvonne Tran - Officer | Open-market sale | Common Stock | 1,094 | $12.90 footnote F2 | $14K | |
| ||||||
| Ramy Farid - Officer | Open-market sale | Common Stock | 3,661 | $12.91 footnote F2 | $47K | |
| ||||||
| Karen Akinsanya - Officer | Open-market sale | Common Stock | 1,366 | $12.90 footnote F2 | $18K | |
| ||||||
| Kenneth Patrick Lorton - Officer | Open-market sale | Common Stock | 1,222 | $12.90 footnote F2 | $16K | |
| ||||||
| Robert Lorne Abel - Officer | Open-market sale | Common Stock | 1,300 | $12.81 | $17K | |
| Richard Friesner - Director | Option exercise | Common Stock | 160,527 | $3.07 | $493K | |
| Richard Friesner - Director | Option exercise | Stock Option (right to buy) | 160,527 | $0.00 | - | |
| Ramy Farid - Officer | Grant or award | Common Stock | 56,250 | $0.00 | - | |
| Ramy Farid - Officer | Grant or award | Common Stock | 13,604 | $0.00 | - | |
| Ramy Farid - Officer | Grant or award | Common Stock | 48,259 | $0.00 | - | |
| Ramy Farid - Officer | Open-market sale | Common Stock | 5,560 | $11.90 footnote F5 | $66K | |
| Ramy Farid - Officer | Grant or award | Stock Option (right to buy) | 112,500 | $0.00 | - | |
| ||||||
| Rachit Jain - Officer | Grant or award | Common Stock | 17,130 | $0.00 | - | |
| Rachit Jain - Officer | Grant or award | Stock Option (right to buy) | 34,250 | $0.00 | - | |
| Yvonne Tran - Officer | Grant or award | Common Stock | 17,130 | $0.00 | - | |
| Yvonne Tran - Officer | Grant or award | Common Stock | 13,788 | $0.00 | - | |
| Yvonne Tran - Officer | Grant or award | Stock Option (right to buy) | 34,250 | $0.00 | - | |
| Kenneth Patrick Lorton - Officer | Grant or award | Common Stock | 17,130 | $0.00 | - | |
| Kenneth Patrick Lorton - Officer | Grant or award | Common Stock | 20,682 | $0.00 | - | |
| Kenneth Patrick Lorton - Officer | Grant or award | Stock Option (right to buy) | 34,250 | $0.00 | - | |
| Jenny Herman - Officer | Grant or award | Common Stock | 9,590 | $0.00 | - | |
| Jenny Herman - Officer | Grant or award | Stock Option (right to buy) | 8,220 | $0.00 | - | |
| Karen Akinsanya - Officer | Grant or award | Common Stock | 24,250 | $0.00 | - | |
| Karen Akinsanya - Officer | Grant or award | Common Stock | 6,077 | $0.00 | - | |
| Karen Akinsanya - Officer | Grant or award | Common Stock | 27,576 | $0.00 | - | |
| Karen Akinsanya - Officer | Open-market sale | Common Stock | 2,206 | $11.99 footnote F5 | $26K | |
| Karen Akinsanya - Officer | Grant or award | Stock Option (right to buy) | 48,500 | $0.00 | - | |
| ||||||
 Mannix Vartan Aklian - Officer | Grant or award | Common Stock | 17,130 | $0.00 | - | |
| Mannix Vartan Aklian - Officer | Grant or award | Stock Option (right to buy) | 34,250 | $0.00 | - | |
| Robert Lorne Abel - Officer | Grant or award | Common Stock | 17,130 | $0.00 | - | |
| Robert Lorne Abel - Officer | Grant or award | Common Stock | 20,682 | $0.00 | - | |
| Robert Lorne Abel - Officer | Grant or award | Stock Option (right to buy) | 34,250 | $0.00 | - | |
Item 2.02, 9.01
Item 7.01
Item 5.02, 5.07, 9.01
Item 5.02, 9.01
Recent SDGR Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| KAREN OLUFUNMILYO AKINSANYA-AKIWUMI | Officer | 31,599 | $756K | View on EDGAR | |
| - | - | - | - |
SDGR insider trading FAQ
What is the latest insider trade for SDGR?
Schrodinger, Inc. (SDGR) had 2 insider filings in the last 90 days, with the most recent on 2026-09-21. The full record for SDGR runs to 38 Form 4 filings, the earliest from 2024-10-16. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SDGR stock?
No insider purchases of SDGR were filed in the last 90 days.
How many insiders are selling SDGR stock?
3 insider sales of SDGR were filed in the last 90 days, totaling $942K.
Where can I see SDGR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SDGR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Karen Akinsanya view on EDGAR
- - Rachit Jain view on EDGAR
- - Richard Friesner view on EDGAR
- - Arun Oberoi view on EDGAR
- - Jeffrey Chodakewitz view on EDGAR
- - Richard Friesner view on EDGAR
- - Gary L. Ginsberg view on EDGAR
- - Rosana Kapeller-Libermann view on EDGAR
- - Michael Lynton view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where SDGR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SDGR with a 7-day demo
- SDGR on your watchlist
- Every SDGR Form 4 filing on record
- Up to 3 months of SDGR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
